Synaptogenix (TAOX) Stock Price, News & Analysis

Company Overview

Synaptogenix, Inc. operates as a biopharmaceutical company with product candidates in pre-clinical and clinical development. It focuses on developing a product platform based upon a drug candidate called Bryostatin-1 for the treatment of Alzheimer's disease. The company is also evaluating therapeutic applications of bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as fragile X syndrome, multiple sclerosis, and Niemann-pick type C disease. Synaptogenix, Inc. has licensing agreements with Stanford University; Icahn School of Medicine at Mount Sinai; and The Board of Trustees of the Leland Stanford Junior University. The company was incorporated in 2012 and is headquartered in New York, New York.

Key Stats

• Today's Range: $6.23 to $7.00
• 50-Day Range: N/A
• 52-Week Range: $1.84 to $11.98
• Volume: 205,610 shs
• Average Volume: 363,212 shs
• Market Capitalization: $9.54 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

TAOX Stock Analysis - Frequently Asked Questions

How have TAOX shares performed this year?

Synaptogenix's stock was trading at $8.41 at the beginning of 2025. Since then, TAOX stock has decreased by 18.4% and is now trading at $6.86.

How do I buy shares of Synaptogenix?

Shares of TAOX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

• Today: 7/29/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Manufacturing
• Industry: Pharmaceutical Preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:TAOX
• CIK: 1571934
• Web: N/A
• Phone: (973) 242-0005
• Fax: N/A
• Employees: 4
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): ($10.08)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$12.77 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -115.28%
• Return on Assets: -58.31%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 72.59
• Quick Ratio: 72.59

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $4.33 per share
• Price / Book: 1.61

Miscellaneous

• Outstanding Shares: 1,390,000
• Free Float: 1,352,000
• Market Cap: $9.69 million
• Optionable: N/A
• Beta: 1.90